ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) — Healthcare · Share Price, Chart & Market Data
About: ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.21 (+10.53%)
ZVSAZyVersa Therapeutics Inc.
Loading watchlist status…
Trade ZVSA now
ZyVersa Therapeutics Inc. share price
ZVSA price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 9:11 am GMT+0
ZVSA price performance
-4.545%
5D
8.192%
1M
56.134%
YTD
-68.893%
1Y
ZVSA price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 9:11 am GMT+0
ZVSA details
ZVSA Market Signals